# reload+after+2024-01-20 14:36:02.544307
address1§Creo House
address2§Unit 2, Beaufort Park Beaufort Park Way
city§Chepstow
zip§NP16 5UH
country§United Kingdom
phone§44 12 9160 6005
fax§44 12 9160 6015
website§https://creomedical.com
industry§Medical Devices
industryKey§medical-devices
industryDisp§Medical Devices
sector§Healthcare
sectorKey§healthcare
sectorDisp§Healthcare
longBusinessSummary§Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for flexible endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device designed for soft tissue ablation; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highly perfused tissues. In addition, it provides endotherapy accessories comprising ScopeSnare, an energy-based polypectomy snares; ScopeSnare Cold, a cutting wire for use in endoscopically in the removal of diminutive, sessile and pedunculated polyps, and tissue from within the GI tract; ScopeClip, a single-use rotational and repositionable hemoclips; ScopeBite, a portfolio of biopsy forceps; ScopeGrasp, a portfolio of grasping forceps; and ScopeInject, an injection needle. Creo Medical Group PLC was founded in 2003 and is based in Chepstow, the United Kingdom.
fullTimeEmployees§279
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Craig Jonathan Gulliford', 'age': 52, 'title': 'CEO & Executive Director', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 472658, 'exercisedValue': 0, 'unexercisedValue': 126198}, {'maxAge': 1, 'name': 'Prof. Christopher Paul Hancock', 'age': 55, 'title': 'Founder, CTO & Executive Director', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 360174, 'exercisedValue': 0, 'unexercisedValue': 41830}, {'maxAge': 1, 'name': 'Mr. Richard John Rees ACA', 'age': 46, 'title': 'CFO, Company Secretary & Executive Director', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 359804, 'exercisedValue': 0, 'unexercisedValue': 24624}, {'maxAge': 1, 'name': 'Mr. David Gerard Woods', 'age': 57, 'title': 'Chief Commercial Officer & Executive Director', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 446377, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Phil  Hales', 'title': 'Sales & Marketing Director', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.891
priceToSalesTrailing12Months§5.6775317
currency§GBp
forwardEps§-3.22
exchange§LSE
quoteType§EQUITY
shortName§CREO MEDICAL GROUP PLC ORD GBP0
longName§Creo Medical Group PLC
firstTradeDateEpochUtc§1481270400
timeZoneFullName§Europe/London
timeZoneShortName§GMT
uuid§9e19bf83-d6bc-31a1-8148-43916ff7e7cd
messageBoardId§finmb_206505629
targetHighPrice§100.0
targetLowPrice§99.0
targetMeanPrice§99.5
targetMedianPrice§99.5
recommendationMean§1.0
recommendationKey§strong_buy
numberOfAnalystOpinions§2
quickRatio§3.454
grossMargins§0.48249
ebitdaMargins§-0.87813
trailingPegRatio§None
